Skip to main content

Table1 Clinicopathologic parameters of 13 HR+HER2− breast cancer patients

From: METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2—breast cancer

Variables

n (%)

Age (years)

 

 Median

52.00

Clinical T stage

 

 cT1-2

6 (46.2)

 cT3-4

7 (53.8)

NAC regimen

 

 AC-T/P

11 (84.6)

 TAC

2 (15.4)

NAC cycles

 

 ≤ 4

9 (69.2)

 > 4

4 (30.8)

Residual tumour size

 

 ≤ 2 cm

1 (7.7)

 > 2 cm

12 (92.3)

Nodal status

 

 Neg

5 (38.5)

 Pos

8 (61.5)

  1. NAC neoadjuvant chemotherapy